CELH vs. VRNA

Last updated Jun 9, 2026

CELH (Celsius Holdings, Inc.) and VRNA (Verona Pharma plc) are both stocks. CELH operates in Beverages - Non-Alcoholic (Consumer Defensive), while VRNA operates in Biotechnology (Healthcare). At a 0.10 correlation, their price movements are largely independent.

Performance

CELH vs. VRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Celsius Holdings, Inc. (CELH) and Verona Pharma plc (VRNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

CELH

• 1D: -0.46%
• 1M: -13.29%
• YTD: -38.78%
• 6M: -36.79%
• 1Y: -31.03%
• 3Y*: -15.49%
• 5Y*: 2.92%
• 10Y*: 42.06%

VRNA

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

CELH vs. VRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
CELH Celsius Holdings, Inc.	-38.78%	73.65%	-51.69%	57.21%	39.52%	48.22%	941.61%	39.19%	-33.90%	31.91%
VRNA Verona Pharma plc	0.00%	130.21%	133.60%	-23.92%	288.84%	-4.00%	21.74%	-40.41%	-18.71%	-12.07%

Correlation

The correlation between CELH and VRNA is 0.12, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.12
Correlation (3Y) Calculated over the trailing 3-year period	0.11
Correlation (5Y) Calculated over the trailing 5-year period	0.14
Correlation (All Time) Calculated using the full available price history since Apr 27, 2017	0.10

Fundamentals

Market Cap CELH : $7.27B VRNA : $9.72B
EPS CELH : $0.61 VRNA : -$0.69
PS Ratio CELH : 2.29 VRNA : 57.97
PB Ratio CELH : 18.26 VRNA : 34.92
Total Revenue (TTM) CELH : $2.97B VRNA : $167.65M
Gross Profit (TTM) CELH : $1.47B VRNA : $159.52M
EBITDA (TTM) CELH : $274.27M VRNA : -$40.86M

Return for Risk

CELH vs. VRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CELH

CELH Risk / Return Rank: 20
CELH Sharpe Ratio Rank: 18
CELH Sortino Ratio Rank: 21
CELH Omega Ratio Rank: 20
CELH Calmar Ratio Rank: 23
CELH Martin Ratio Rank: 20

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CELH vs. VRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Celsius Holdings, Inc. (CELH) and Verona Pharma plc (VRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CELH	VRNA	Difference
Sharpe ratio: Return per unit of total volatility	-0.55	—	—
Sortino ratio: Return per unit of downside risk	-0.49	—	—
Omega ratio: Gain probability vs. loss probability	0.94	—	—
Calmar ratio: Return relative to maximum drawdown	-0.54	—	—
Martin ratio: Return relative to average drawdown	-1.06	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	CELH	VRNA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.55	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.04	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.62	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.64	—	—

Drawdowns

Drawdown Indicators

	CELH	VRNA	Difference
Max Drawdown Largest peak-to-trough decline	-77.86%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-57.22%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-77.86%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-77.86%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-77.86%	—	—
Current Drawdown Current decline from peak	-70.87%	—	—
Average Drawdown Average peak-to-trough decline	-27.86%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	29.34%	—	—

Volatility

Volatility by Period

	CELH	VRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	18.92%	—	—
Volatility (6M) Calculated over the trailing 6-month period	37.51%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	56.59%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	65.66%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	68.94%	—	—

Dividends

CELH vs. VRNA - Dividend Comparison

Neither CELH nor VRNA has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

CELH vs. VRNA - Profitability Comparison

The chart below illustrates the profitability comparison between Celsius Holdings, Inc. and Verona Pharma plc over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

CELH - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Celsius Holdings, Inc. reported a gross profit of 378.07M and revenue of 782.62M. Therefore, the gross margin over that period was 48.3%.

VRNA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a gross profit of 71.68M and revenue of 75.14M. Therefore, the gross margin over that period was 95.4%.

CELH - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Celsius Holdings, Inc. reported an operating income of 138.99M and revenue of 782.62M, resulting in an operating margin of 17.8%.

VRNA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported an operating income of 9.69M and revenue of 75.14M, resulting in an operating margin of 12.9%.

CELH - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Celsius Holdings, Inc. reported a net income of 85.08M and revenue of 782.62M, resulting in a net margin of 10.9%.

VRNA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Verona Pharma plc reported a net income of 8.69M and revenue of 75.14M, resulting in a net margin of 11.6%.

Frequently Asked Questions

Can I hold both CELH and VRNA in my portfolio?

CELH and VRNA have a correlation of 0.12, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.